Cargando…

Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection

During the COVID‐19 pandemic, Portugal has experienced three distinct SARS‐CoV‐2 infection waves. We previously documented the prevalence of SARS‐CoV‐2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Canto e Castro, Luísa, Gomes, Andreia, Serrano, Marta, Pereira, Ana Helena Guia, Ribeiro, Rita, Napoleão, Patrícia, Domingues, Inês, Silva, Cláudia, Fanczal, Júlia, Afonso, Ângela, Lopes, Andreia, Toader, Ionela, de Sousa, Maria José Rego, de Sousa, José Germano Rego, de Sousa, Germano, Mota, Maria M., Silva‐Santos, Bruno, Veldhoen, Marc, Ribeiro, Ruy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646574/
https://www.ncbi.nlm.nih.gov/pubmed/34695227
http://dx.doi.org/10.1002/eji.202149619
_version_ 1784610499427565568
author Canto e Castro, Luísa
Gomes, Andreia
Serrano, Marta
Pereira, Ana Helena Guia
Ribeiro, Rita
Napoleão, Patrícia
Domingues, Inês
Silva, Cláudia
Fanczal, Júlia
Afonso, Ângela
Lopes, Andreia
Toader, Ionela
de Sousa, Maria José Rego
de Sousa, José Germano Rego
de Sousa, Germano
Mota, Maria M.
Silva‐Santos, Bruno
Veldhoen, Marc
Ribeiro, Ruy M.
author_facet Canto e Castro, Luísa
Gomes, Andreia
Serrano, Marta
Pereira, Ana Helena Guia
Ribeiro, Rita
Napoleão, Patrícia
Domingues, Inês
Silva, Cláudia
Fanczal, Júlia
Afonso, Ângela
Lopes, Andreia
Toader, Ionela
de Sousa, Maria José Rego
de Sousa, José Germano Rego
de Sousa, Germano
Mota, Maria M.
Silva‐Santos, Bruno
Veldhoen, Marc
Ribeiro, Ruy M.
author_sort Canto e Castro, Luísa
collection PubMed
description During the COVID‐19 pandemic, Portugal has experienced three distinct SARS‐CoV‐2 infection waves. We previously documented the prevalence of SARS‐CoV‐2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8–18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long‐lasting infection immunity against SARS‐CoV‐2. Moreover, vaccinated people had higher IgG levels from 3 weeks post‐vaccination when compared with previously infected people at the same time post‐infection.
format Online
Article
Text
id pubmed-8646574
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86465742021-12-06 Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection Canto e Castro, Luísa Gomes, Andreia Serrano, Marta Pereira, Ana Helena Guia Ribeiro, Rita Napoleão, Patrícia Domingues, Inês Silva, Cláudia Fanczal, Júlia Afonso, Ângela Lopes, Andreia Toader, Ionela de Sousa, Maria José Rego de Sousa, José Germano Rego de Sousa, Germano Mota, Maria M. Silva‐Santos, Bruno Veldhoen, Marc Ribeiro, Ruy M. Eur J Immunol Immunity to infection During the COVID‐19 pandemic, Portugal has experienced three distinct SARS‐CoV‐2 infection waves. We previously documented the prevalence of SARS‐CoV‐2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8–18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long‐lasting infection immunity against SARS‐CoV‐2. Moreover, vaccinated people had higher IgG levels from 3 weeks post‐vaccination when compared with previously infected people at the same time post‐infection. John Wiley and Sons Inc. 2021-11-10 2022-01 /pmc/articles/PMC8646574/ /pubmed/34695227 http://dx.doi.org/10.1002/eji.202149619 Text en © 2021 The Authors. European Journal of Immunology published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Immunity to infection
Canto e Castro, Luísa
Gomes, Andreia
Serrano, Marta
Pereira, Ana Helena Guia
Ribeiro, Rita
Napoleão, Patrícia
Domingues, Inês
Silva, Cláudia
Fanczal, Júlia
Afonso, Ângela
Lopes, Andreia
Toader, Ionela
de Sousa, Maria José Rego
de Sousa, José Germano Rego
de Sousa, Germano
Mota, Maria M.
Silva‐Santos, Bruno
Veldhoen, Marc
Ribeiro, Ruy M.
Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
title Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
title_full Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
title_fullStr Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
title_full_unstemmed Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
title_short Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
title_sort longitudinal sars‐cov‐2 seroprevalence in portugal and antibody maintenance 12 months after infection
topic Immunity to infection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646574/
https://www.ncbi.nlm.nih.gov/pubmed/34695227
http://dx.doi.org/10.1002/eji.202149619
work_keys_str_mv AT cantoecastroluisa longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT gomesandreia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT serranomarta longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT pereiraanahelenaguia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT ribeirorita longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT napoleaopatricia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT dominguesines longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT silvaclaudia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT fanczaljulia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT afonsoangela longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT lopesandreia longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT toaderionela longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT desousamariajoserego longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT desousajosegermanorego longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT desousagermano longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT motamariam longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT silvasantosbruno longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT veldhoenmarc longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection
AT ribeiroruym longitudinalsarscov2seroprevalenceinportugalandantibodymaintenance12monthsafterinfection